secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001645113-24-000009
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure METIS Phase 3 trial meets primary endpoint; intracranial progression delay 21.9 vs 11.3 months
--------------------------------------------------------------------------------

- TTFields + supportive care showed median time to intracranial progression of 21.9 months vs 11.3 months for supportive care alone (HR=0.67, p=0.016).
- Key secondary endpoints (neurocognitive failure, overall survival, radiological response) did not reach statistical significance.
- Median TTFields therapy duration was 16 weeks, median usage 67%; therapy well-tolerated with sustained quality of life.
- Novocure plans to submit data to regulatory authorities and publish findings in a peer-reviewed journal.
- Phase 3 METIS trial enrolled 298 patients with 1-10 brain metastases from NSCLC following stereotactic radiosurgery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000009/0001645113-24-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000009/nvcr-20240327.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer